Prognosis of patients with brain metastases from HER2-positive breast cancer

Study	Time period	Number of patients	Median survival after CNS recurrence
Tham, et al^[1]	1970-1999	21	~3 months
Bendell, et al^[2]	1998-2000	42	13 months
Gori, et al^[3]	1999-2005	43	23 months
Stemmler, et al^[4]	2000-2004	42	13 months
Eichler, et al^[5]	2001-2005	30	17 months
Melisko, et al^[6]	1997-2007	35	23 months
Brufsky, et al ^[7]	2003-2009	377	20.3 months

Trastuzumab approved by the United States Food and Drug Administration (FDA) for treatment of HER2-positive, metastatic breast cancer in 1998.

CNS: central nervous system; HER2: human epidermal growth factor receptor 2.

References:

Tham YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107:696.
Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 97:2972.
Gori S, Rimondini S, De Angelis V, et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007; 12:766.
Stemmler HJ, Kahlert S, Siekiera W, et al. Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. Breast 2006; 15:219.
Eichler AF, Kuter I, Ryan P, et al. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 2008; 112:2359.
Melisko ME, Moore DH, Sneed PK, et al. Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neurooncol 2008; 88:359.
Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 2011; 17:4834.

Graphic 80803 Version 3.0